Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CHRISTENSEN

Showing results (501-510 of 608) with videos related to

Pageof 61
Sort By:
European Journal of Clinical Investigation|May 31, 2001
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failureH G Eiken, E Øie, J K Damås, et al.
Genes, Chromosomes & Cancer|August 19, 2008
Expression and mutational analysis of MET in human solid cancersPatrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, et al.
The British Journal of Nutrition|December 1, 2022
Rationale and design of IMPACT-women: a randomised controlled trial of the effect of time-restricted eating, healthy eating and reduced sedentary behaviour on metabolic health during chemotherapy for early-stage breast cancerRebecca A G Christensen, Mark J Haykowsky, Michelle Nadler, et al.
Scientific Reports|May 22, 2021
The TGF-β ligand DBL-1 is a key player in a multifaceted probiotic protection against MRSA in C. elegansMaria G M Mørch, Katrine V Møller, Marianne O Hesselager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Cancer Discovery|May 16, 2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro-Oonuma, Ying Wei, et al.
The American Journal of Pathology|May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosisEmily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Acta Oncologica (Stockholm, Sweden)|April 11, 2023
The association between education and fear of recurrence among breast cancer patients in follow-up - and the mediating effect of self-efficacyCecilie Larsen, Kirstine S Kirchhoff, Lena Saltbæk, et al.
Pageof 61

Showing results (501-510 of 608) with videos related to

Sort By:
Pageof 61
European Journal of Clinical Investigation|May 31, 2001
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failureH G Eiken, E Øie, J K Damås, et al.
Genes, Chromosomes & Cancer|August 19, 2008
Expression and mutational analysis of MET in human solid cancersPatrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, et al.
The British Journal of Nutrition|December 1, 2022
Rationale and design of IMPACT-women: a randomised controlled trial of the effect of time-restricted eating, healthy eating and reduced sedentary behaviour on metabolic health during chemotherapy for early-stage breast cancerRebecca A G Christensen, Mark J Haykowsky, Michelle Nadler, et al.
Scientific Reports|May 22, 2021
The TGF-β ligand DBL-1 is a key player in a multifaceted probiotic protection against MRSA in C. elegansMaria G M Mørch, Katrine V Møller, Marianne O Hesselager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Cancer Discovery|May 16, 2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro-Oonuma, Ying Wei, et al.
The American Journal of Pathology|May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosisEmily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Acta Oncologica (Stockholm, Sweden)|April 11, 2023
The association between education and fear of recurrence among breast cancer patients in follow-up - and the mediating effect of self-efficacyCecilie Larsen, Kirstine S Kirchhoff, Lena Saltbæk, et al.
Pageof 61